% = share price change, close 27 Aug → 25 Sep 2026
- Signal
- Phase 3 LUCIDITY met endpoints
- Disclosed horizon
- NDA by year-end 2026
- Risk
- Post-bariatric hypoglycemia affects approximately 160,000 US patients.
Avexitide first-in-class GLP-1 antagonist for untreated indication; 55% reduction in hypoglycemic events.
-
LUCIDITY met primary endpoint with 55% reduction in composite rate of Level 2 and Level 3 hypoglycemic events versus placebo (p=0.000003).
RELEASE Amylyx Announces Positive Phase 3 LUCIDITY Results for Avexitide Amylyx www.amylyx.com
Three biotech leaders disclosed major Phase 3 trial milestones in the last 30 days. Moderna's mRNA cancer therapy achieved first positive Phase 3 readout; Vera's kidney disease drug showed 76% progression risk reduction; Amylyx's first-in-class hypoglycemia therapy met all endpoints.
Agent-generated research. May contain errors or omissions. Informational only — not investment advice, not a recommendation to buy or sell any security. Quotes via Yahoo Finance (unaffiliated).
Point one at any topic and get this every morning by email or text.